COVID-19 associated cognitive impairment: A systematic review

Predominance of visuoconstructive impairment after mild COVID-19?

“…Research on the neuropsychological performance after SARS-CoV-2 infection is needed to better understand the consequences of COVID-19. Growing body of evidence confirms the presence of cognitive, neuroimaging and pathological implications of SARS-CoV-2 infection [ 2 – 5 ], and this study adds scientific contributions to the field. However, we would like to highlight some results from the present study that captured our attention.…”

“…For instance, in our experience, in patients after 9 months from the acute phase, we found no impairment in ROCF copy compared with the normative data, while other cognitive domains such as attention, executive functions and memory showed dysfunction [ 5 ]. According to the other case series reported up to date using comprehensive neuropsychological assessment and normative data or healthy controls as reference, cognitive profile in patients after COVID-19 (especially in those reporting cognitive complaints) is usually characterized by a predominant attention/processing speed dysfunction, executive and episodic memory deficits [ 2 , 5 , 6 ]. Conversely, tests such as the copy of a complex figure are largely preserved or only impaired in patients with impairment in several cognitive domains [ 5 , 7 ].…”

Evolution of physical function, cognition, depressive mood, and quality of life during the Covid-19 pandemic in prefrail elderly people: A longitudinal cohort study (Covid-Mefap)

“…Having had COVID-19 was associated with a worsening of 54 % in cognition, which was likely related to the neurological impairment widely described at the clinical level ( Tavares-Júnior et al, 2022 ). In contrast, other potentially related variables, such as the time spent reading, doing memory exercises, or using social networks online, showed no association with the cognitive function in our population.…”

Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild–moderate COVID-19 and prevention of post-COVID cognitive impairment

“…According to various studies, these post-COVID-19 symptoms are observed in about a third of patients who have suffered from COVID-19 of varying severity (Taquet et al 2021 ; Nalbandian et al 2021 ; Huang et al 2021 ; Baker et al 2021 ; Crivelli et al 2022 ). There is increasing evidence that cognitive impairment is widely observed among the consequences of COVID-19 disease, even in patients who have developed mild disease symptoms (Tavares-Júnior et al 2022 ; Crivelli et al 2022 ; Ceban et al 2022 ; Hadad et al 2022 ). The proportion of individuals with cognitive impairment after COVID-19 has been inconsistent, but a prospective follow-up study reported that 48–56% of patients may have cognitive impairment after severe COVID-19 infection (Miskowiak et al 2022 ).…”